<DOC>
	<DOCNO>NCT00002381</DOCNO>
	<brief_summary>To determine potential effect 28 day nevirapine treatment steady-state pharmacokinetics nelfinavir stavudine ( d4T ) , evaluate pharmacokinetics nevirapine combination nelfinavir , d4T compare historical control treat nevirapine without nelfinavir d4T . To determine efficacy long-term combination therapy nevirapine , nelfinavir d4T viral load patient non-nucleoside reverse transcriptase inhibitor ( NNRTI ) protease inhibitor naive , &lt; = 6 month prior d4T exposure time screening .</brief_summary>
	<brief_title>The Safety Effectiveness Nevirapine Plus Nelfinavir HIV-1 Infected Patients Who Have Taken Stavudine</brief_title>
	<detailed_description>The trial open-label study patient HIV-1 infection naive treatment NNRTI protease inhibitor class antiretroviral drug &lt; = 6 month prior exposure d4T time screen . Part I trial investigation potential pharmacokinetic interaction nevirapine nelfinavir HIV-1-infected adult treat d4T . Part II investigation long-term antiviral activity combination nevirapine nelfinavir viral load measure HIV-1 RNA .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<mesh_term>Stavudine</mesh_term>
	<mesh_term>Nelfinavir</mesh_term>
	<criteria>Inclusion Criteria Patients must : Documented HIV infection . CD4+ cell count &gt; = 100 cells/mm3 . Plasma HIV1 RNA &gt; = 5000 copies/ml . Prior Medication : Allowed : Previous antiretroviral therapy zidovudine , lamivudine , didanosine , dideoxycytidine . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Malabsorption , severe chronic diarrhea , inability maintain adequate oral intake . Undergoing treatment active infection . Hepatic insufficiency due cirrhosis . Renal insufficiency . 1 . Systemic treatment corticosteroid drug know hepatic enzyme inducer inhibitor within 14 day entry . Substances category include : macrolide antibiotic ( erythromycin , clarithromycin , azithromycin , dirithromycin ) , azole antifungal ( ketoconazole , fluconazole , itraconazole ) , rifampin , rifabutin , phenytoin . Previous exposure nonnucleoside reverse transcriptase inhibitor ( NNRTIs ) delavirdine , loviride , DMP 266 , nevirapine and/or protease inhibitor ( PI ) saquinavir , ritonavir , indinavir , nelfinavir . &gt; 6 month previous exposure d4T . Investigational drug within 30 day first dose study medication . Any antineoplastic agent within 12 week start study medication . Radiotherapy , local skin radiotherapy treatment , within 12 week prior study . 1 . History intravenous drug abuse alcohol substance abuse consider Investigator BIPI Medical Monitor significant impairment health compliance . Heavy smoker ( e.g. , &gt; 20 cigarette per day ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2002</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Nevirapine</keyword>
	<keyword>Stavudine</keyword>
	<keyword>RNA , Viral</keyword>
	<keyword>Nelfinavir</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>Viral Load</keyword>
</DOC>